Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Evanston Police Pension Fund v. McKesson Corporation et al
Case Number:
3:18-cv-06525
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Bleichmar Fonti
- DiCello Levitt
- Robbins Geller
- Sidley Austin
- Simpson Thacher & Bartlett LLP
- Wilson Elser
Companies
Sectors & Industries:
-
July 14, 2023
McKesson Investor Attys Get $35M For $141M Price Fix Deal
Robbins Geller Rudman & Dowd LLP attorneys who represent a class of McKesson investors will receive $35 million in fees from a $141 million settlement for their work on litigation alleging the company made false assertions concerning a drug price-fixing scheme, according to an order issued in California federal court on Friday.
-
November 04, 2022
McKesson OKs $141M Investor Deal Over Generic Price-Fixing
McKesson will pay shareholders $141 million to resolve class action claims in federal court in California over its allegedly false assertions about generic drug prices that plaintiffs traced to a generic-drug price-fixing conspiracy, according to an investor filing.
-
October 21, 2021
McKesson Nears Win On Some Securities Fraud Claims
A California federal judge appeared inclined Thursday to grant McKesson summary judgment on some securities fraud claims over its alleged participation in a generic drug price-fixing scheme, asking repeatedly what difference it would make to shareholders if they knew McKesson's artificial prices were caused by anti-competitive conduct and not inflation.
-
October 30, 2019
McKesson Can't Ditch Generic Drug Price-Fixing Fraud Suit
McKesson Corp. must face securities fraud claims over its alleged participation in an industry-wide generic drug price-fixing scheme, a California federal court ruled Wednesday, denying the drug wholesaler's bid to escape the suit.
-
October 18, 2019
McKesson Faces Uphill Fight To Toss Investor Price-Fix Suit
A California federal judge appeared skeptical Friday of McKesson Corp.'s bid to toss investors' claims that they were misled as part of its alleged participation in an industry-wide conspiracy to drive up generic drug prices, saying the proposed class had adequately stated that the drug company's alleged lies caused them harm.